Form 4: Director Peter A. Thompson Sells Sionna Therapeutics Stock

Director Peter A. Thompson reported the sale of 101 shares of Sionna Therapeutics, Inc. common stock via a 10b5-1 trading plan.

Summary

• Director Peter A. Thompson sold 101 shares of Sionna Therapeutics (SION) common stock.
• The transaction occurred on May 27, 2026, at a price of $44.49 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, the reporting person maintains an indirect beneficial ownership of 2,671,721 shares held by OrbiMed Private Investments VIII, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the transaction is a routine, pre-planned sale of a very small number of shares by an institutional director.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• Insider selling activity, even when pre-planned, can sometimes be perceived negatively by retail investors as a signal of management sentiment.

Risks

• The reporting person disclaims beneficial ownership of the shares held by OrbiMed Private Investments VIII, LP, except to the extent of their pecuniary interest, highlighting the complexity of the ownership structure.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales via 10b5-1 plans are common in the biotechnology sector, particularly among venture capital-backed firms where directors represent institutional investors managing liquidity for their funds.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.
• The scale of the sale (101 shares) is negligible relative to the total holdings of over 2.6 million shares, suggesting this is a routine administrative transaction rather than a strategic divestment.

Related Party Transactions

• The shares are held by OrbiMed Private Investments VIII, LP, where the reporting person is a member of the managing entity, OrbiMed Advisors LLC.

Stakeholder Impact

• Minimal impact on shareholders given the de minimis size of the transaction.

Key Dates

Keywords

Sionna Therapeutics, SION, Insider Trading, Form 4, OrbiMed, Biotech